Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease

Journal of Neurosurgery

Volumn 102, Issue 1, 2005, Pages 80-89

  Yasuhara, Takao ^a   Shingo, Tetsuro ^a   Muraoka, Kenichiro ^a   Kobayashi, Kazuki ^a   Takeuchi, Akira ^a   Yano, Akimasa ^a   Wenji, Yuan ^a   Kameda, Masahiro ^a   Matsui, Toshihiro ^a   Miyoshi, Yasuyuki ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Dopaminergic neuron; Encapsulation; Glial cell line derived neurotrophic factor; Glial cell line derived neurotrophic factor receptor 1; Neuroprotection; Parkinson disease; Rat

Indexed keywords

AMPHETAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; TYROSINE 3 MONOOXYGENASE; ADRENERGIC RECEPTOR STIMULATING AGENT; GDNF PROTEIN, RAT; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL ENCAPSULATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; CELL LINE; DISEASE MODEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; METHODOLOGY; PATHOLOGY; ROTATION; SPRAGUE DAWLEY RAT; TIME;

ADRENERGIC AGENTS; AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CELL LINE; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TRANSFER TECHNIQUES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; TIME FACTORS;

EID: 13844280470     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2005.102.1.0080     Document Type: Article

References (39)

1. Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA, et al: Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 461:250-261, 2003
2. Aoi M, Date I, Tomita S, Ohmoto T: GDNF induces recovery of the nigrostriatal dopaminergic system in the rat brain following intracerebroventricular or intraparenchymal administration. Acta Neurochir 142:805-810, 2000
3. Aoi M, Date I, Tomita S, Ohmoto T: Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism. Restor Neurol Neurosci 17:31-38, 2001
4. Arjona V, Minguez-Castellanos A, Montoro RJ, Ortega A, Escamilla F, Toledo-Aral JJ, et al: Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 53:321-330, 2003
5. Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ: Neuroprotective effects of prior limb use in 6-hydroxydopaminetreated rats: possible role of GDNF. J Neurochem 85:299-305, 2003
6. Cunningham LA, Su C: Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol 174:230-242, 2002
7. Date I, Asari S, Nishimoto A, Felten DL: [Adrenal medullary graft induces recovery of the host nigrostriatal dopaminergic system in MPTP-induced mouse model of Parkinson's disease.] No To Shinkei 42:1173-1178, 1990 (Jpn)
8. Date I, Shingo T, Yoshida H, Fujiwara K, Kobayashi K, Takeuchi A, et al: Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant 10:397-401, 2001
9. Eggert K, Schlegel J, Oertel W, Wurz C, Krieg JC, Vedder H: Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neurosci Lett 269:178-182, 1999
10. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719, 2001
11. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595, 2003
12. Hanbury R, Ling ZD, Wuu J, Kordower JH: GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults. J Comp Neurol 461:307-316, 2003
13. Harvey BK, Chang CF, Chiang YH, Bowers WJ, Morales M, Hoffer BJ, et al: HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp Neurol 183:47-55, 2003
14. Hebb AO, Hebb K, Ramachandran AC, Mendez I: Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage. J Neurosurg 98:1078-1083, 2003
15. Ikeda T, Xia XY, Xia YX, Ikenoue T, Han B, Choi BH: Glial cell line-derived neurotrophic factor protects against ischemia/hypoxia-induced brain injury in neonatal rat. Acta Neuropathol 100:161-167, 2000
16. Insua MF, Garelli A, Rotstein NP, German OL, Arias A, Politi LE: Cell cycle regulation in retinal progenitors by glia-derived neurotrophic factor and docosahexaenoic acid. Invest Ophthalmol Vis Sci 44:2235-2244, 2003
17. Kirik D, Georgievska B, Rosenblad C, Bjorklund A: Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 13:1589-1599, 2001
18. Kordower JH: In vivo gene delivery of glial cell line - derived neurotrophic factor for Parkinson's disease. Ann Neurol 53 (Suppl 3):S120-S134, 2003
19. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, et al: Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46:419-424, 1999
20. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F: GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132, 1993
21. Marco S, Saura J, Perez-Navarro E, Jose Marti M, Tolosa E, Alberch J: Regulation of c-Ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease. J Neurobiol 52:343-351, 2002
22. Maswood N, Grondin R, Zhang Z, Stanford JA, Surgener SP, Gash DM, et al: Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23:881-889, 2002
23. Nicole O, Ali C, Docagne F, Plawinski L, MacKenzie ET, Vivien D, et al: Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci 21:3024-3033, 2001
24. Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199, 1991
25. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al: Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69-73, 2003
26. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414, 2003
27. Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, et al: Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22:4942-4954, 2002
28. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press, 1998
29. Shingo T, Date I, Yoshida H, Ohmoto T: Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J Neurosci Res 69:946-954, 2002
30. Shingo T, Sorokan ST, Shimazaki T, Weiss S: Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21:9733-9743, 2001
31. Smith AD, Antion M, Zigmond MJ, Austin MC: Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRalpha1 and RET mRNAs in the adult rat. Brain Res Mol Brain Res 117:129-138, 2003
32. Toledo-Aral JJ, Mendez-Ferrer S, Pardal R, Echevarria M, Lopez-Barneo J: Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. J Neurosci 23:141-148, 2003
33. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, et al: Characterization of a multicomponent receptor for GDNF. Nature 382:80-83, 1996
34. Ugarte SD, Lin E, Klann E, Zigmond MJ, Perez RG: Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J Neurosci Res 73:105-112, 2003
35. Wang Y, Chang CF, Morales M, Chiang YH, Hoffer J: Protective effects of glial cell line-derived neurotrophic factor in ischemic brain injury. Ann NY Acad Sci 962:423-437, 2002
36. Winkler C, Sauer H, Lee CS, Bjorklund A: Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16:7206-7215, 1996
37. Worby CA, Vega QC, Zhao Y, Chao HH, Seasholtz AF, Dixon JE: Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 271:23619-23622, 1996
38. Yasuhara T, Shingo T, Kobayashi K, Takeuchi A, Yano A, Muraoka K, et al: Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci 19:1494-1504, 2004
39. Yoshida H, Date I, Shingo T, Fujiwara K, Kobayashi K, Miyoshi Y, et al: Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: a preclinical primate study. J Neurosurg 98:874-881, 2003